Taken together, the consistent downregulation of CXCL14 across multiple aggressive BC subtypes and its association with shorter OS indicate that it may serve as a prognostic marker and therapeutic target, particularly through its role in immune modulation and tumor microenvironment regulation. The gene discussed is CXCL14; the disease is neoplasm.